182 related articles for article (PubMed ID: 37334144)
1. Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML.
Chen X; Zhao Y; Li Q; Fan S
Onco Targets Ther; 2023; 16():409-419. PubMed ID: 37334144
[TBL] [Abstract][Full Text] [Related]
2. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
[No Abstract] [Full Text] [Related]
3. Venetoclax combined with hypomethylating agents and the CAG regimen in relapsed/refractory AML: a single-center clinical trial.
Liu Y; Li Y; Zhang R; Yu Z; Jing Y
Front Immunol; 2023; 14():1269163. PubMed ID: 38054008
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience.
Angotzi F; Lessi F; Leoncin M; Filì C; Endri M; Lico A; Visentin A; Pravato S; Candoni A; Trentin L; Gurrieri C
Front Oncol; 2024; 14():1370405. PubMed ID: 38680863
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and Survival of Venetoclax Based Regimen in the Treatment of Acute Myeloid Leukemia].
Kong FC; Qi L; Huang WF; Yu M; Zhou YL; Ji DX; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1676-1683. PubMed ID: 38071045
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia.
Fleischmann M; Scholl S; Frietsch JJ; Hilgendorf I; Schrenk K; Hammersen J; Prims F; Thiede C; Hochhaus A; Schnetzke U
J Cancer Res Clin Oncol; 2022 Nov; 148(11):3191-3202. PubMed ID: 35099591
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
[No Abstract] [Full Text] [Related]
8. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.
DiNardo CD; Rausch CR; Benton C; Kadia T; Jain N; Pemmaraju N; Daver N; Covert W; Marx KR; Mace M; Jabbour E; Cortes J; Garcia-Manero G; Ravandi F; Bhalla KN; Kantarjian H; Konopleva M
Am J Hematol; 2018 Mar; 93(3):401-407. PubMed ID: 29218851
[TBL] [Abstract][Full Text] [Related]
9. Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.
Graveno ME; Carulli A; Freyer CW; Mangan BL; Nietupski R; Loren AW; Frey NV; Porter DL; Gill SI; Hexner EO; Luger SM; Martin ME; McCurdy SR; Perl AE; Babushok DV; Pratz KW
Leuk Lymphoma; 2022 Jul; 63(7):1645-1650. PubMed ID: 35259056
[TBL] [Abstract][Full Text] [Related]
10. Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
Weng G; Huang J; He X; Xue T; Yang L; Zhang Y; Yu G; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Jin H; Liu Q; Du X
Ann Hematol; 2023 Dec; 102(12):3369-3381. PubMed ID: 37723307
[TBL] [Abstract][Full Text] [Related]
11. [The Efficacy and Safety of Venetoclax Combined with Azacitidine in the Treatment of Adult Patients with Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy].
Wang KY; Fan BR; Zhang QW; Han MR; Ge XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):342-346. PubMed ID: 38660834
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Abaza Y; Winer ES; Murthy GSG; Shallis RM; Matthews AH; Badar T; Geramita EM; Kota VK; Swaroop A; Doukas P; Bradshaw D; Helenowski IB; Liu Y; Zhang H; Im A; Litzow MR; Perl AE; Atallah E; Altman JK
Am J Hematol; 2024 Apr; 99(4):606-614. PubMed ID: 38342997
[TBL] [Abstract][Full Text] [Related]
13. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
Aldoss I; Zhang J; Mei M; Al Malki MM; Arslan S; Ngo D; Aribi A; Ali H; Sandhu K; Salhotra A; Koller P; Khaled S; Artz A; Snyder D; Nakamura R; Forman SJ; Stein AS; Marcucci G; Pullarkat V
Am J Hematol; 2020 Oct; 95(10):1193-1199. PubMed ID: 32628327
[TBL] [Abstract][Full Text] [Related]
15. Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia.
Weng G; Zhang Y; Yu G; Luo T; Yu S; Xu N; Sun Z; Lin D; Deng L; Liang X; Xiao J; Zhang H; Guo Z; Shao R; Du X; Jin H; Liu Q
J Intern Med; 2023 Mar; 293(3):329-339. PubMed ID: 36284445
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and Safety of Venetoclax-Based Induction Therapy in Acute Myeloid Leukemia].
Feng J; Yuan RF; Tang HL; Bai QX; Yang L; Dong HJ; Liang R; Zhang T; Gu HT; Gao GX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Auguest; 31(4):960-966. PubMed ID: 37551462
[TBL] [Abstract][Full Text] [Related]
17. Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.
Xu X; Liu R; He A; Wang F
Hematology; 2023 Dec; 28(1):2265206. PubMed ID: 37796109
[TBL] [Abstract][Full Text] [Related]
18. Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience.
Gaut D; Burkenroad A; Duong T; Feammelli J; Sasine J; Schiller G
Leuk Res; 2020 Mar; 90():106314. PubMed ID: 32035355
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of Therapeutic Efficacy between Hypomenthylating Agents Combined with Venetoclax and Half Dose Priming Regimen in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia].
Xu MZ; Qiao M; Sun AN; Wu DP; Xue SL; Zhou HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1631-1636. PubMed ID: 36476881
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and granulocyte colony-stimulating factor chemotherapy as a first-line therapy for newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
Huang R; He H; Xu X; Lin X; Dong Y; Wang X; Jiang F; Huang P; Mo S; Huang Z; Wang Y; Tao H; Zheng Y; Wu M; Yang C; Zheng Z; Zhao Y; Zhang Y; Li Y
Cancer; 2024 Mar; ():. PubMed ID: 38470375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
